These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17180387)

  • 1. Thrombotic thrombocytopenic purpura secondary to mifepristone in a patient of medical termination in early pregnancy.
    Chung LW; Yeh SP; Hsieh CY; Chiu CF
    Ann Hematol; 2007 May; 86(5):385-6. PubMed ID: 17180387
    [No Abstract]   [Full Text] [Related]  

  • 2. Fatal infections associated with mifepristone-induced abortion.
    Greene MF
    N Engl J Med; 2005 Dec; 353(22):2317-8. PubMed ID: 16319378
    [No Abstract]   [Full Text] [Related]  

  • 3. Atypical presentation of serious pelvic inflammatory disease following mifepristone-induced medical abortion.
    Sparrow M; Shand C; Macdonald J
    Contraception; 2006 Oct; 74(4):352-3; author reply 353-4. PubMed ID: 16982242
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol.
    Guest J; Chien PF; Thomson MA; Kosseim ML
    BJOG; 2007 Feb; 114(2):207-15. PubMed ID: 17305893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of mifepristone abortion in context.
    Grimes DA
    Contraception; 2006 Aug; 74(2):174-5 author reply175-6. PubMed ID: 16860058
    [No Abstract]   [Full Text] [Related]  

  • 6. Risks of mifepristone abortion in context.
    Crockett SA
    Contraception; 2006 Aug; 74(2):174; author reply 175-6. PubMed ID: 16860057
    [No Abstract]   [Full Text] [Related]  

  • 7. Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial.
    von Hertzen H; Piaggio G; Wojdyla D; Marions L; My Huong NT; Tang OS; Fang AH; Wu SC; Kalmar L; Mittal S; Erdenetungalag R; Horga M; Pretnar-Darovec A; Kapamadzija A; Dickson K; Anh ND; Tai NV; Tuyet HT; Peregoudov A;
    BJOG; 2009 Feb; 116(3):381-9. PubMed ID: 19187370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public health advisory for mifepristone.
    FDA Consum; 2005; 39(5):4-5. PubMed ID: 16421985
    [No Abstract]   [Full Text] [Related]  

  • 9. Toxic epidermal necrolysis after mifepristone/gemeprost-induced abortion.
    Lecorvaisier-Pieto C; Joly P; Thomine E; Tanasescu S; Noblet C; Lauret P
    J Am Acad Dermatol; 1996 Jul; 35(1):112. PubMed ID: 8682946
    [No Abstract]   [Full Text] [Related]  

  • 10. [Medical abortion].
    Ottesen BS
    Ugeskr Laeger; 1999 May; 161(22):3263. PubMed ID: 10485201
    [No Abstract]   [Full Text] [Related]  

  • 11. Mifepristone-induced abortion and placental complications in subsequent pregnancy.
    Zhu QX; Gao ES; Chen AM; Luo L; Cheng YM; Yuan W
    Hum Reprod; 2009 Feb; 24(2):315-9. PubMed ID: 19054774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mifepristone: less obvious adverse effects.
    Rudd G
    Ann Pharmacother; 2001 Mar; 35(3):381-2. PubMed ID: 11261540
    [No Abstract]   [Full Text] [Related]  

  • 13. [Medical termination of pregnancy in a patient with severe cystic fibrosis. Possible effect of the antiglucocorticoid action of mifepristone on the respiratory disease].
    Guerci P; Vial F; Raft J; Nelis UM; Mory S; Morel O; Bouaziz H
    Ann Fr Anesth Reanim; 2013 Feb; 32(2):115-7. PubMed ID: 23286887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vasospastic angina pectoris following abortion induced by prostaglandin analogue].
    Lindhardt TB; Walker LR; Colov NS; Hansen PS
    Ugeskr Laeger; 2000 Nov; 162(48):6536-7. PubMed ID: 11187221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval of mifepristone (RU 486) in Europe.
    Sitruk-Ware R
    Zentralbl Gynakol; 2000; 122(5):241-7. PubMed ID: 10857210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiprogesterones--new prospects in induced abortion].
    Karag'ozov I; Chernev T
    Akush Ginekol (Sofiia); 1994; 33(2):47-9. PubMed ID: 7485784
    [No Abstract]   [Full Text] [Related]  

  • 17. Risks of mifepristone abortion in context.
    Grimes DA
    Contraception; 2005 Mar; 71(3):161. PubMed ID: 15722063
    [No Abstract]   [Full Text] [Related]  

  • 18. Making unsafe abortion safe: medical method.
    Pradhan P
    Nepal Med Coll J; 2004 Dec; 6(2):147-51. PubMed ID: 16295750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.
    Svedas E; Maciulaitis R; Stakisaitis D
    Ann Pharmacother; 2006 Apr; 40(4):784; author reply 784-5. PubMed ID: 16595574
    [No Abstract]   [Full Text] [Related]  

  • 20. Comment: analysis of severe adverse events related to the use of mifepristone as an abortifacient.
    Shannon CS
    Ann Pharmacother; 2006 Jun; 40(6):1215-6; author reply 1216-7. PubMed ID: 16735658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.